No abstract

BackgroundOur study group established "3H care" in 2002. The meaning of "3H care" attain and maintain adequate controls over hypertension, hyperlipidemia, and hyperglycemia in type 2 diabetic patients. This study evaluated the achievement of target goals after one year or more of "3H care" by specialists in our diabetic clinic.MethodsThis was a retrospective study of 200 type 2 diabetic patients who received "3H care" for one year or more in our diabetic clinic. We evaluated achievement of target goals for metabolic controls as suggested by the American Diabetes Association.ResultsOverall, 200 type 2 diabetes patients were enrolled, of whom 106 were males (53%) and 94 were females (47%). After one year of "3H care," the mean HbA1c was 7.2±1.5% and the percentage of patients achieving glycemic control (HbA1c <7%) was 51.8%. However only 32.2% of hypertensive patients achieved the recommended target. After one year of "3H care," the percentages of those who achieved the target value for dyslipidemia were 80.0% for total cholesterol, 66.3% for low density lipoprotein cholesterol, 57.9% for triglyceride, and 51.8% for high density lipoprotein cholesterol. The percentage that achieved all three targets level was only 4.4% after one year and 14.8% after two years.ConclusionThe results of this study demonstrate that only a minor proportion of patients with type 2 diabetes achieved the recommended goals despite the implementation of "3H care." It is our suggestion that better treatment strategies and methods should be used to control hypertension, hyperlipidemia and hyperglycemia.

No abstract

Background and Objectives：Cardiac troponin I (cTnI) is a sensitive and specific marker of myocardial injury. Although myocardial infarction due to coronary artery occlusion is the most common cause of cTnI elevation, its rise has been reported in non-coronary artery diseases such as paroxysmal tachycardia. This study was conducted to determine the incidence of cTnI elevation in supraventricular tachycardia and to identify the factors associated with the rise in cTnI. Subjects and Methods：We studied sixty-nine patients (35 males and 34 females, average age: 59±14 years) who were admitted for supraventricular tachycardia without evidence of coronary artery disease between January 2001 and December 2004. Coronary artery disease was excluded on the basis of clinical examinations, non-invasive techniques or coronary angiography. The subjects comprised 31 patients with paroxysmal supraventricular tachycardia, 36 patients with atrial fibrillation and 2 patients with atrial flutter. Results：Serum cTnI elevation was observed in 22 of the 69 patients (31.9%) with supraventricular tachycardia. Multiple regression analysis revealed interventricular septal thickness (p<0.0001), the diastolic left ventricular internal dimension (p=0.0416) and hypertension (p=0.0460) as the significant factors related to cTnI elevation. However, the type or duration of tachycardia, the heart rate during tachycardia and patient's age were not related to cTnI elevation. Conclusion：This study showed that cTnI elevation may occur not infrequently in the patients with supraventricular tachycardia even in the absence of coronary artery disease. Myocardial hypertrophy and hypertension were the important factors related to cTnI elevation in this setting.

No abstract